Why is Humana stock surging today?

Humana's stock surged 12.6% in after-hours trading on Thursday following the Centers for Medicare & Medicaid Services' (CMS) release of the 2027 Medicare Advantage Star Ratings. The ratings revealed that Humana's flagship H5216 contract had improved from 3.5 stars to 4 stars, reinstating the company's eligibility for federal quality bonus payments.

This development marked a significant recovery from a 2024 ratings collapse that had reduced Humana's share of top-rated plans from 94% to 25%, severely impacting the insurer's bonus income and profitability outlook. The post-market spike was driven by bullish analyst activity ahead of the CMS release, with Cantor Fitzgerald upgrading Humana to Overweight from Neutral and raising its price target to $460, while Barclays also moved to Overweight with a $515 target, citing the H5216 contract and the October CMS ratings release as key upside catalysts.

This surge stood in stark contrast to the flat performance of the broader market, with the S&P 500, Dow Jones, and Nasdaq all essentially unchanged. The recovery was entirely driven by Humana-specific regulatory news and did not coincide with any macro or sector-wide tailwinds.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.